The safe and effective use of hormonal birth control can be significantly influenced by medications commonly administered during the perioperative period. This issue is of particular concern for patients of reproductive age who may be unaware of the potential for drug interactions to reduce contraceptive efficacy, thereby increasing the risk of unintended pregnancy. Understanding the mechanisms, recognizing high-risk medications, and implementing preventive strategies are essential for optimal perioperative care.

Most hormonal birth control methods, including combined oral contraceptives and progestin-only pills, rely on continuous hormone levels to prevent ovulation. These hormones, such as ethinyl estradiol and various progestins, are metabolized primarily in the liver by cytochrome P450 enzymes. Medications that induce these enzymes can accelerate hormone breakdown, leading to reduced contraceptive effectiveness. Conversely, some drugs inhibit these enzymes, potentially increasing hormone levels and associated side effects.

Several medications used in the perioperative setting can interact with hormonal birth control. For example, sugammadex, a reversal agent for neuromuscular blockade, binds to progesterone and can lower its serum levels for up to a week following administration. This effect is comparable to missing a daily contraceptive dose and necessitates the use of backup contraception during this period. Aprepitant, an antiemetic, also interacts with hormonal contraceptives by inhibiting cytochrome P450 enzymes, leading to decreased hormone levels that may persist for nearly a month. Other perioperative drugs, such as certain antibiotics and anticonvulsants, can also induce these enzymes and reduce contraceptive efficacy.

The clinical consequences of these interactions are significant. Reduced hormone levels increase the risk of ovulation and unintended pregnancy, especially if alternative contraception is not used. It is important to note that simply increasing the dose of hormonal contraceptives is not an effective strategy to overcome these interactions. Instead, patients should be advised to use barrier methods or other non-hormonal forms of contraception during the period of risk. Progestin-only injectables are less affected by enzyme-inducing drugs and may offer a suitable alternative in some cases.

In addition to the risk of contraceptive failure, drug interactions can also lead to irregular bleeding or other side effects. Elevated hormone levels, which may occur with enzyme inhibitors, can increase the risk of thrombosis, although this is rare with short-term perioperative use.

Preventive strategies are essential to minimize these risks. Preoperative counseling should include screening for contraceptive use and a discussion of potential drug interactions. Alternative medications, such as neostigmine instead of sugammadex or ondansetron instead of aprepitant, should be considered when possible. For elective surgeries, it may be appropriate to discontinue enzyme-inducing drugs several weeks in advance if clinically safe. Patients should also receive clear, written instructions regarding the need for backup contraception and the appropriate duration of its use.

Anesthesia providers play a critical role in safeguarding birth control efficacy during the perioperative period. By recognizing high-risk medications, implementing alternatives, and prioritizing patient education, the risk of unintended pregnancy and related complications can be minimized. Collaborative protocols involving surgeons, anesthesiologists, and pharmacists are essential to standardize these practices and ensure the best outcomes for patients.

References

1. Whitney M, Sharpe EE, Harbell MW, Buckner-Petty S, Kraus MB. Anesthesia Providers’ Knowledge of Medication Interference with Hormonal Contraception: A Multisite Survey. Anesth Analg. 2025 Jan 1;140(1):145-154. doi: 10.1213/ANE.0000000000007081. Epub 2024 Oct 4. PMID: 39365740.
2. Devoy T, Smith N. Sugammadex and oral contraceptives. Curr Opin Anaesthesiol. 2024 Aug 1;37(4):338-343. doi: 10.1097/ACO.0000000000001397. Epub 2024 Jun 3. PMID: 38841921.
3. Bailard N, Rebello E. Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. Br J Clin Pharmacol. 2018 Mar;84(3):602-603. doi: 10.1111/bcp.13472. Epub 2017 Dec 19. PMID: 29266364; PMCID: PMC5809356.
4. Aljindan F, Allababidi NH, Mortada H, Alhumaid F, Alzaidi SA. The Preoperative Management of Oral Contraceptive Pills in Aesthetic Plastic Surgery Practice in Saudi Arabia. Cureus. 2022 Nov 5;14(11):e31121. doi: 10.7759/cureus.31121. PMID: 36479411; PMCID: PMC9720713.
5. Chattha A, Brown E, Slavin S, Lin S. Oral Contraceptive Management in Aesthetic Surgery: A Survey of Current Practice Trends. Aesthet Surg J. 2018 Feb 15;38(3):NP56-NP60. doi: 10.1093/asj/sjx234. PMID: 29267904.